Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Clinical Trial to Determine the Most Appropriate Time to Start HIV Treatment in HIV and TB Coinfected Adults Being Treated for Tuberculosis.

Trial Profile

Randomized Clinical Trial to Determine the Most Appropriate Time to Start HIV Treatment in HIV and TB Coinfected Adults Being Treated for Tuberculosis.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efavirenz (Primary) ; Ethambutol; Isoniazid; Lamivudine; Pyrazinamide; Rifampicin; Stavudine
  • Indications HIV infections; Tuberculosis
  • Focus Therapeutic Use
  • Acronyms TB-HAART
  • Most Recent Events

    • 29 Apr 2016 Status changed from active, no longer recruiting to completed, according to the results published.
    • 29 Apr 2016 Long-term results (n=493) of pharmacokinetic parameters of efavirenz and its metabolites were published in the Journal of Clinical Pharmacology.
    • 08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top